Cargando…

Feasibility Study of a Network Meta-Analysis and Unanchored Population-Adjusted Indirect Treatment Comparison of Niraparib, Olaparib, and Bevacizumab as Maintenance Therapies in Patients with Newly Diagnosed Advanced Ovarian Cancer

SIMPLE SUMMARY: Ovarian cancer (OC) is a leading cause of cancer-related death and 85% of women with advanced OC relapse after chemotherapy. First-line (1L) maintenance therapy is given to prolong the benefit of chemotherapy. However, selection of a 1L maintenance therapy is challenging given the nu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lorusso, Domenica, Guy, Holly, Samyshkin, Yevgeniy, Hawkes, Carol, Estenson, Kasey, Coleman, Robert L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Systematic Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909094/ https://www.ncbi.nlm.nih.gov/pubmed/35267593 http://dx.doi.org/10.3390/cancers14051285

Ejemplares similares

Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States
por: Guy, Holly, et al.
Publicado: (2018)

Cost-Effectiveness of Niraparib and Olaparib as Maintenance Therapy for Patients with Platinum-Sensitive Recurrent Ovarian Cancer
por: Zhong, Lixian, et al.
Publicado: (2018)

Performance of unanchored matching-adjusted indirect comparison (MAIC) for the evidence synthesis of single-arm trials with time-to-event outcomes
por: Jiang, Yawen, et al.
Publicado: (2020)

Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial
por: Barretina-Ginesta, Maria-Pilar, et al.
Publicado: (2022)

Quantitative determination of niraparib and olaparib tumor distribution by mass spectrometry imaging
por: Morosi, Lavinia, et al.
Publicado: (2020)

Unanchored Ubiquitin Chains, Revisited
por: Blount, Jessica R., et al.
Publicado: (2020)

Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab versus bevacizumab alone in women with newly diagnosed advanced ovarian cancer
por: Hettle, Robert, et al.
Publicado: (2021)

Comment on: “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States”
por: Wallace, Katrine, et al.
Publicado: (2019)

MassChemSite for In-Depth Forced Degradation Analysis of PARP Inhibitors Olaparib, Rucaparib, and Niraparib
por: Bonciarelli, Stefano, et al.
Publicado: (2023)

Direct Activation of Protein Kinases by Unanchored Polyubiquitin Chains
por: Xia, Zong-Ping, et al.
Publicado: (2009)

Expression and Regulation of Deubiquitinase-Resistant, Unanchored Ubiquitin Chains in Drosophila
por: Blount, Jessica R., et al.
Publicado: (2018)

Olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer: Japan subset from the PAOLA-1/ENGOT-ov25 trial
por: Fujiwara, Keiichi, et al.
Publicado: (2021)

Cost-effectiveness of fuzuloparib compared to routine surveillance, niraparib and olaparib for maintenance treatment of patients with germline BRCA1/2 mutation and platinum-sensitive recurrent ovarian carcinoma in China
por: Nie, Jing, et al.
Publicado: (2023)

Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Phase 3 Randomized Clinical Trial
por: Li, Ning, et al.
Publicado: (2023)

Case Report: Niraparib as Maintenance Therapy in A Patient With Ovarian Carcinosarcoma
por: Zhang, Jie Qing, et al.
Publicado: (2021)

Comment on ‘Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab versus bevacizumab alone in women with newly diagnosed advanced ovarian cancer’. (Ther Adv Med Oncol. 2021 Sep 30;13:17588359211049639)
por: Nakai, Hidekatsu, et al.
Publicado: (2023)

Olaparib and bevacizumab in front-line maintenance of ovarian cancer: an over reliance in unpowered subgroup analysis of the PAOLA-1 trial?
por: Paulino, Eduardo, et al.
Publicado: (2020)

Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer
por: Lee, Arnold
Publicado: (2021)

Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer
por: Elsea, David, et al.
Publicado: (2022)

Niraparib for ovarian cancer
Publicado: (2021)

Author response to ‘Comment on “Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab versus bevacizumab alone in women with newly diagnosed advanced ovarian cancer” (Ther Adv Med Oncol. 2021 Sep 30;13:17588359211049639)’
por: Hettle, Robert, et al.
Publicado: (2023)

Quantification of cobimetinib, cabozantinib, dabrafenib, niraparib, olaparib, vemurafenib, regorafenib and its metabolite regorafenib M2 in human plasma by UPLC–MS/MS
por: Krens, Stefanie D., et al.
Publicado: (2020)

Unanchored ubiquitin chains do not lead to marked alterations in gene expression in Drosophila melanogaster
por: Blount, Jessica R., et al.
Publicado: (2019)

Percutaneous retrieval of an unanchored WiSE-CRT system left ventricular receiver electrode
por: Okabe, Toshimasa, et al.
Publicado: (2020)

Budget impact analysis of niraparib for first-line maintenance therapy in advanced ovarian cancer from a US payer perspective
por: Liu, Jinan, et al.
Publicado: (2021)

Correction to: Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer
por: Elsea, David, et al.
Publicado: (2022)

Correction to: Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer
por: Lee, Arnold
Publicado: (2021)

Protein Aggregates Are Recruited to Aggresome by Histone Deacetylase 6 via Unanchored Ubiquitin C Termini
por: Ouyang, Hui, et al.
Publicado: (2012)

Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy
por: Lorusso, Domenica, et al.
Publicado: (2018)

Safety Profile of Niraparib as Maintenance Therapy for Ovarian Cancer: A Systematic Review and Meta-Analysis
por: Pagkali, Antonia, et al.
Publicado: (2022)

Retrospective efficacy analysis of olaparib combined with bevacizumab in the treatment of advanced colorectal cancer
por: Jiang, Yi-Ling, et al.
Publicado: (2023)

An Indirect Comparison of the Efficacy and Safety of Dostarlimab and Doxorubicin for the Treatment of Advanced and Recurrent Endometrial Cancer
por: Mathews, Cara, et al.
Publicado: (2022)

Role of Olaparib as Maintenance Treatment for Ovarian Cancer: The Evidence to Date
por: Montemorano, Lauren, et al.
Publicado: (2019)

Rucaparib and Niraparib in Advanced Ovarian Cancer
por: Redelico, Tyler
Publicado: (2019)

The cost-effectiveness analysis of maintenance olaparib plus Bevacizumab in patients with advanced ovarian cancer: based on the final survival results from PAOLA-1 trial
por: Zhu, Youwen, et al.
Publicado: (2023)

Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial
por: Pujade-Lauraine, Eric, et al.
Publicado: (2023)

Unanchored tri‐NEDD8 inhibits PARP‐1 to protect from oxidative stress‐induced cell death
por: Keuss, Matthew J, et al.
Publicado: (2019)

Ad hoc Analysis of the Phase III ENGOT-OV16/NOVA Study: Niraparib Efficacy in Germline BRCA Wild-type Recurrent Ovarian Cancer with Homologous Recombination Repair Defects
por: Mirza, Mansoor Raza, et al.
Publicado: (2022)

LC-MS/MS Method for the Quantification of PARP Inhibitors Olaparib, Rucaparib and Niraparib in Human Plasma and Dried Blood Spot: Development, Validation and Clinical Validation for Therapeutic Drug Monitoring
por: Canil, Giovanni, et al.
Publicado: (2023)

Cost-effectiveness of maintenance niraparib with an individualized starting dosage in patients with platinum-sensitive recurrent ovarian cancer in China
por: Shi, Yin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_e3s0omik940hp75e0emt93o21i